Endogena Therapeutics, Inc. — Form D
Endogena Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2021-01-05. The offering totals $8.0M, of which $8.0M was reported sold. Industry: Other.
Offering
- Filed: 2021-01-05
- Form: D
- Accession: 0001838748-21-000001
- Industry: Other
- Exemptions: 06b
- Total offering: $8.0M
- Amount sold: $8.0M
- Remaining: $75
- Minimum investment: $1
- Investors: 13
- Date of first sale: 2020-12-21
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-385229
Issuer
- Name: Endogena Therapeutics, Inc.
- CIK: 0001838748
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 111 PINE STREET, SAN FRANCISCO, CA, 94111
- Phone: 415-433-2262
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Dirk Harbecke | Director | Toronto, A6 |
| Aaron Weaver | Director | Irvine, CA |
| Markus Bertini | Executive Officer | San Francisco, CA |
| Daniel Zabrowski | Director | San Francisco, CA |
| Elona Baum | Director | San Francisco, CA |
| Matthias Steger | Director | San Francisco, CA |
| Matthias Steger | Executive Officer | San Francisco, CA |
Other filings by this issuer (1)
More